Adaptive Biotechnologies Corporation (ADPT) — Stock Score Summary

Adaptive Biotechnologies Corporation (ADPT) has a MoatMap StockRank of 22/100 based on Quality (38/100), Value (35/100), and Momentum (36/100) factor scores. The current signal is SELL. Adaptive Biotechnologies (US, Healthcare) is a biotech company focused on immunosequencing. Its success is highly dependent on specific technological adoption and clinical outcomes, which are disconnected from the fund's macro thematic investment approach.

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that sequences the adaptive immune system to develop clinical diagnostics and drug discovery solutions. It holds a proprietary immune medicine platform that analyzes T-cell and B-cell receptor repertoires, providing unparalleled insights into the immune system for disease detection and drug development. Adaptive is a leader in immune sequencing technology, aiming to transform disease diagnosis and treatment by leveraging the power of the adaptive immune system.

Key Financial Metrics

Price$15.19
Market Cap$2.4B
P/E (Forward)-54.95
Price/Book10.43
Return on Equity-24.0%
Return on Invested Capital-11.3%
Debt/Equity92.84
Gross Margin43.7%
Operating Margin-27.1%
Revenue Growth35.1%
Free Cash Flow$16M

Adaptive Biotechnologies Corporation operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Adaptive Biotechnologies Corporation’s (ADPT) StockRank?
MoatMap’s StockRank for Adaptive Biotechnologies Corporation (ADPT) is 22/100, with a Sell signal. It is a composite of Quality (38), Value (35), and Momentum (36) factor ranks across MoatMap’s 19,000+ stock universe.
Does Adaptive Biotechnologies Corporation have an economic moat?
Adaptive Biotechnologies Corporation (ADPT) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Adaptive Biotechnologies Corporation a buy, hold, or sell?
MoatMap’s current signal for Adaptive Biotechnologies Corporation (ADPT) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Adaptive Biotechnologies Corporation in?
Adaptive Biotechnologies Corporation (ADPT) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).
Browse all ranked stocksADPT deep dive reportAI ChampionsHow we score stocksSense-check another stock